Nope, dead on arrival..
OncoGel, an experimental drug delivery system combining paclitaxel (an anticancer drug) with ReGel (a biodegradable gel for slow release), is not currently used in patients in the United States or elsewhere, based on available information. Clinical trials, primarily conducted in the late 2000s, evaluated OncoGel for esophageal cancer and recurrent glioblastoma, but these studies were terminated, often due to sponsor decisions rather than safety or efficacy concerns. For example, a Phase 2 trial for esophageal cancer (NCT00573131) and a Phase 1/2 trial for glioblastoma were discontinued, with no clear evidence of progression to widespread clinical use.
There is no indication from recent data that OncoGel has been approved by the FDA or is in routine clinical practice in the US. The lack of current references to its use, beyond terminated trials, suggests it is not commercially available or widely used. Research seems to have shifted toward other localized drug delivery systems, such as Gliadel for glioblastoma, which is FDA-approved but has limitations that OncoGel was intended to address.
$RDGL
Market Data 
Markets 
AI
